key: cord-0853945-b993e984
authors: Ferrara, Skylar J.; Chaudhary, Priya; DeBell, Margaret J.; Marracci, Gail; Miller, Hannah; Calkins, Evan; Pocius, Edvinas; Napier, Brooke A.; Emery, Ben; Bourdette, Dennis; Scanlan, Thomas S.
title: TREM2 is thyroid hormone regulated making the TREM2 pathway druggable with ligands for thyroid hormone receptor
date: 2021-01-27
journal: bioRxiv
DOI: 10.1101/2021.01.25.428149
sha: 778ceaf488e521b7175a2ccaf1ab5c47f678293c
doc_id: 853945
cord_uid: b993e984

Triggering receptor expressed on myeloid cells-2 (TREM2) is a cell surface receptor on macrophages and microglia that senses and responds to disease associated signals to regulate the phenotype of these innate immune cells. The TREM2 signaling pathway has been implicated in a variety of diseases ranging from neurodegeneration in the central nervous system to metabolic disease in the periphery. We report here that TREM2 is a thyroid hormone regulated gene and its expression in macrophages and microglia is stimulated by thyroid hormone. Both endogenous thyroid hormone and sobetirome, a synthetic thyroid hormone agonist drug, suppress pro-inflammatory cytokine production from myeloid cells including macrophages that have been treated with the SARS-CoV-2 spike protein which produces a strong, pro-inflammatory phenotype. Thyroid hormone agonism was also found to induce phagocytic behavior in microglia, a phenotype consistent with activation of the TREM2 pathway. The thyroid hormone antagonist NH-3 blocks the anti-inflammatory effects of thyroid hormone agonists and suppresses microglia phagocytosis. Finally, in a murine experimental autoimmune encephalomyelitis (EAE) multiple sclerosis model, treatment with Sob-AM2, a CNS-penetrating sobetirome prodrug, results in increased Trem2 expression in disease lesion resident myeloid cells which correlates with therapeutic benefit in the EAE clinical score and reduced damage to myelin. Our findings represent the first report of endocrine regulation of TREM2 and provide a unique opportunity to drug the TREM2 signaling pathway with orally active small molecule therapeutic agents.

Thyroid hormone (TH) provides essential regulation of many critical processes in vertebrate biology. 1 Thyroxine (T4) is the predominant form of TH produced in and secreted from the thyroid gland, but its deiodinated metabolite 3,5,3'-triiodothyronine (T3) is the active form of TH that binds thyroid hormone receptors (TR) with high affinity. TRs bind to regulatory DNA sequences called thyroid hormone response elements (TRE) in the promoter regions of TH regulated genes, and T3 binding to TR in the cell nucleus activates TR to either stimulate or suppress transcription of these genes. Through such regulation of target genes TH action plays an important developmental role in the central nervous system (CNS) and periphery, as well as regulation of metabolism and homeostasis in many organs and cell types in the periphery. It is and in vivo by treatment with T3, or the peripheral and CNS-penetrating thyromimetic agents sobetirome and Sob-AM2, respectively. This discovery effectively renders TREM2 "druggable" by systemically dosed small molecules with sufficient drug-like properties for targeting the TREM2 pathway in either the CNS or periphery.

Our interest in TREM2 was initiated from reports that microglia and macrophages increased phagocytic capacity upon treatment with the retinoid X receptor (RXR) agonist bexarotene, 11 and treatment of TREM2-expressing myeloid lineage cells with other nuclear receptor agonists including PPAR and LXR also stimulated phagocytosis. 12 Based on comprehensive genome-wide studies in mice, it has been reported that the Trem2 gene is regulated by an RXR-dependent enhancer. 13 Because a major biological function of RXR is to form heterodimers at positively-regulated response elements with thyroid hormone receptor (TR) and other members of nuclear receptor family including PPAR and LXR, we examined this enhancer from murine macrophages. We found the following sequence embedded in the putative RXR enhancer of Trem2-AGGGAG-GTTA-AGGTCA-which is a canonical DR4 thyroid hormone response element (TRE) (Fig.1) . The AGGGAG is a consensus half-site for binding RXR, and AGGTCA is a consensus half-site for TR; the four intervening nucleotides (GTTA) make this a positively regulated DR4 TRE which should increase TREM2 expression upon binding thyroid hormone agonists to TR (Fig. 1a) .

We verified that TREM2 expression is indeed positively regulated by thyroid hormone in both murine (Fig. 2a) and human (Fig. 2b ) microglia, murine macrophages (Fig. 2c) , and in mouse brain homogenate (Fig. 2d ). Sobetirome is a synthetic T3 agonist drug that has a larger therapeutic index (TI) than T3, and Sob-AM2 is a prodrug of sobetirome that greatly facilitates delivery of sobetirome to the CNS from a systemic dose (Fig. 1b) . [14] [15] [16] We examined the ability of these agents to drive Trem2 expression and found that sobetirome stimulates Trem2 expression in mouse and human microglia (Fig. 2a,b) , and hypothyroid mice treated with Sob-AM2 (i.p.) had increased Trem2 expressed in brain compared to hypothyroid control (Fig. 2d) .

To verify the involvement of TR in the observed TREM2 regulation by TH, the TR antagonist NH-3 ( Fig. 1b) was employed in combination with T3. 17 NH-3 was not only found to block T3 induction of Trem2 expression in murine microglia, but to suppress Trem2 expression significantly below the basal level observed in vehicle treated cells (Fig. 2a) . As mentioned above, activation of the TREM2 signaling pathway induces both a pro-phagocytic and an antiinflammatory response in monocytes and macrophages. We found that expression of the phagocytic marker Cd68 was increased in microglia by treatment with either T3 or sobetirome, and the T3 effect was blocked by the TR antagonist NH-3 (Fig. 2e ). In addition, expression of the pro-inflammatory cytokine interleukin-1β (IL-1β) was significantly decreased by T3 and sobetirome in mouse primary microglia (Fig. 2f) .

We next examined thyroid hormone regulated gene expression of the pro-inflammatory cytokine interleukin-6 (IL-6) to test the breadth of anti-inflammatory effects that would expected by thyromimetic stimulation of the TREM2 pathway. We tested whether IL-6 expression stimulated from an inflammatory challenge in macrophages could be suppressed by thyromimetic stimulation of TREM2 expression. (Fig. 3) . It has been shown that macrophages incubated with coronavirus (SARS-CoV and SARS-CoV-2) spike S1 protein induce the production of pro-inflammatory cytokines including IL-6. 18-21 RAW 264.7 cells stimulated with SARS-CoV-2 spike S1 protein induced a surge in IL-6 expression compared to unstimulated cells, and this response was significantly attenuated upon treatment with T3 (Fig. 3a) . T3 treatment also significantly suppressed Il6 (Fig. 3b) and Il1b expression (Fig. 3c) in mouse primary lung macrophages stimulated with S1 protein. Concomitant with suppression of these pro-inflammatory cytokines, we observed stimulation of Trem2 expression by T3 in primary lung macrophages (Fig. 3d) .

The finding that TH agonists upregulate both TREM2 and CD68 expression predicts that phagocytosis will be stimulated by these drugs. This prompted us to directly examine phagocytosis, which is an established consequence of TREM2 signaling pathway activation in myeloid lineage cells. In order to ascertain the phagocytic response upon drug treatment, mouse primary microglia were cultured on glass coverslips and treated with drugs in the presence of fluorescent beads used as a phagocytosis substrate that can be monitored and quantified by fluorescence microscopy. 22 Cellular bead uptake was evaluated via 3D volume visualization down orthogonal axes to confirm complete entrapment as shown in Fig. 4g .

Microscopy of cells stained for CD11b microglial expression showed that T3 and sobetirome treatment significantly increased phagocytosis compared to vehicle control as judged by the number of beads engulfed by the microglia (Fig. 4a-c') . Conversely, the T3 antagonist NH-3 treatment was found to suppress phagocytic uptake of beads compared to vehicle-treated control (Fig. 4d,d') . Quantification of these microscopy data demonstrate that TH agonists stimulate, while TH antagonists block, phagocytosis in microglia (Fig. 4h) . These results corroborate existing literature reporting augmented phagocytosis upon T3 treatment in macrophages. 23 We have shown previously that CNS-penetrating thyromimetics stimulate myelin repair in different murine models of demyelination. 24 One such model is experimental autoimmune encephalomyelitis (EAE), which is a demyelination model stimulated by an autoimmune attack that has parallels to the human disease multiple sclerosis. The autoimmune insult in EAE produces demyelination and axonal degeneration, particularly in the lumbar spinal cord region in mice. We have shown that in mice with EAE, T3, sobetirome, and Sob-AM2 treatment reduces clinical disease scores and demyelination and axonal degeneration within the spinal cord. 25 Thus, the question arises as to whether this results in part from thyromimetic stimulation of the TREM2 signaling pathway in microglia and macrophages to induce phagocytosis of myelin debris, which is known to be a prerequisite to myelin repair. 26 EAE was induced in C57Bl/6 mice within a 21-day treatment regimen, where mice were administered once daily injections of vehicle, T3, or Sob-AM2 starting 7 days after immunization before disease onset and continuing until day 21 when euthanasia and tissue collection occurred. Spinal cord sections co-stained with DAPI and TREM2 antibodies in the dorsal white matter of the lumbar section of spinal cords were analyzed for TREM2 content (Fig. 5a-c) . Compared to vehicle, TREM2 protein expression was increased approximately four-fold and three-fold by T3 and Sob-AM2 treatment, respectively (Fig. 5d ). Immunohistochemical analysis of this same spinal cord region showed that the population of CD11b positive cells, which correspond to microglia and/or macrophages, were not statistically different between Sob-AM2 treated mice and vehicle (see Supplementary 

TREM2 has emerged as a central node in the innate immune response governing whether myeloid lineage macrophages and microglia have a pro-inflammatory or antiinflammatory, restorative, healing phenotype in response to pathological insults. Here we report the discovery that TREM2 is a direct target for regulation by thyroid hormone. The promoter region of the TREM2 gene contains a consensus DR4-TRE which presents binding sites for the RXR-TR heterodimer that stimulates TREM2 expression in response to thyroid hormone agonists. We found that TREM2 expression was increased in both microglia and macrophages by addition of either T3 or the synthetic T3 analog sobetirome, and this T3 agonist induction of TREM2 was blocked by the T3 antagonist NH-3. We also found that the proinflammatory cytokines IL-1β and IL-6 that are downregulated by induction of the TREM2 pathway were downregulated by T3 and sobetirome in microglia and macrophages that have been stimulated with the pro-inflammatory SARS-CoV-2 spike protein. Activation of the TREM2 pathway induces phagocytosis in these myeloid cells and T3 and sobetirome were found to induce phagocytosis in microglia whereas the T3 antagonist NH-3 blocked phagocytosis. Finally using the murine EAE model we showed that demyelinated regions of the spinal cord from mice treated with Sob-AM2, a CNS-penetrating prodrug of sobetirome, contained more TREM2 positive cells than control mice. Importantly, mice treated with Sob-AM2 had reduced clinical impairment, demyelination and axonal degeneration, suggesting that thyromimetic stimulation of TREM2 could result in protection in the inflammatory disease EAE. To our knowledge, ours is the first report that TREM2, and by extension the TREM2 pathway, is subject to endocrine regulation.

It has become increasingly apparent that thyroid hormone action plays a role in modulating innate immunity. 27 Control of intracellular T3 levels in macrophages has been shown to be critical for these cells to respond appropriately to inflammatory signals. [28] [29] In addition, thyroid status dictates the degree to which rats respond to an inflammatory insult in which hypothyroidism induces increased pro-inflammatory cytokine production while hyperthyroidism inhibits this response. 30 Administration of T3 blocks NLRP3 inflammasome activation, which depends upon NF-kB activation and results in IL-1β production and release, in different models of liver injury. 31-32 In a model of kidney injury, deletion of the TRα isoforms result in increased injury, and isolated macrophages lacking TRα produce excessive levels of IL-1β compared to WT control. 33 In addition to these examples of driving the transition to an anti-inflammatory phenotype in macrophages, TH has also been shown promote phagocytosis in macrophages, 23 a response that we recapitulated here in microglia treated with T3. Collectively, these myeloid cell observations from both in vitro and in vivo experiments can be explained by thyroid hormone activation of the TREM2 pathway.

The sequelae of Nasu-Hakola disease provides genetic evidence that functional TREM2 and its signaling pathway in myeloid cells is essential for a normal, disease-free human lifespan. 4 Over the past few years it has become increasingly apparent that the biology of the TREM2 signaling pathway is more involved in responding to pathological conditions as opposed to homeostatic physiology. 3 For example, TREM2 is known to play a major role in a disparate collection of diseases including neurodegenerative diseases, 5, 34 metabolic diseases, 7-8 infectious diseases, 35-36 cancer, 9, 37-39 and stroke. 40 Heterozygous missense mutations in TREM2 are associated with strong increased risk of developing late onset Alzheimer's disease (AD), [41] [42] and increased cerebrospinal fluid (CSF) levels of the soluble extracellular domain of TREM2 (sTREM2) has been shown to correlate with less disease severity in AD. 43 This suggests that increased expression of TREM2 and/or increased signaling through the TREM2 pathway in microglia may be therapeutically beneficial in AD. It has also been known for some time that decreased thyroid hormone action in the CNS is detrimental while increased thyroid hormone action in the CNS correlates with clinical benefit in AD and other diseases of cognitive impairment. [44] [45] [46] [47] [48] [49] [50] Our finding that TREM2 is a thyroid hormone regulated gene whose expression is increased by T3 acting on TR in microglia suggests a mechanistic connection between elevated levels of T3 in the CNS and clinical benefit in AD and related disorders. The beneficial effect of increased T3 in the brain may in part relate to increased stimulation of TREM2 expression in microglia and increased activity through the TREM2 pathway.

Another neurodegenerative disease that TREM2 appears associated with is multiple sclerosis (MS), an autoimmune disease that causes inflammatory demyelination and degeneration of axons in the CNS. Similar to AD, sTREM2 levels in the CSF are elevated in both relapsing remitting and primary progressive MS patients compared to CSF from patients 1 0 with non-inflammatory neurological disease. 51 In addition, TREM2-expressing myeloid cells have been detected in CSF and in demyelinating lesions upon autopsy from MS subjects. 51 Macrophages and microglia release proinflammatory cytokines and probably contribute to demyelination and axonal degeneration in MS. In addition, microglia and macrophages play an important role in clearing myelin debris in demyelinating lesions that occur in MS via phagocytosis, which is a prerequisite to forming new myelin from mature oligodendrocytes. 26 We have shown previously that the thyroid hormone receptor agonists sobetirome and Sob-AM2 promote remyelination in murine gliatoxin and genetic models of demyelination, and have further shown that like thyroid hormone, these agents stimulate oligodendrogenesis in vitro and in vivo. 24 Our findings presented here that sobetirome induces TREM2 expression through TR activation in myeloid cells which stimulates phagocytosis in microglia constitutes a second beneficial mechanism of action in addition to oligodendrogenesis for thyroid hormone agonists as myelin repair agents.

This leads to the question of how the TREM2 pathway can be best engaged by drugs for therapeutic benefit. One approach would be to develop TREM2 agonists or antagonists that engage TREM2 directly to activate or block downstream signaling. A problem with this approach is that endogenous ligands for TREM2 appear to be a heterogenous collection of molecules associated with cell damage as opposed to a discrete metabolite or protein which is more amenable to drug discovery approaches. Some success has been reported with anti-TREM2 antibodies that act as agonists upon TREM2 binding, 52-53 but the challenge with biologic agents such as antibodies is their intrinsic limits on distribution to different tissues and compartments affected by disease. For example, distribution from blood to the CNS is difficult with antibodies, and many of the diseases that would benefit from TREM2 engagement are localized in the 1 1 opens the door to a therapeutic approach based on orally active small molecules. A number of studies have demonstrated that increased expression of TREM2 in microglia and/or macrophages alone serves to activate the TREM2 signaling pathway, 43, [54] [55] [56] and this is consistent with our observations that T3 agonists increase TREM2 expression and activate the TREM2 pathway, whereas the T3 antagonist NH-3 blocks TREM2 expression and downstream signaling such as that involved in phagocytosis. The T3 agonist sobetirome would be representative of a drug candidate designed to stimulate the TREM2 pathway in the periphery for therapeutic benefit. Sobetirome therapy would be indicated, for example, for diseases of the liver that may benefit from activation of TREM2 such as NASH, 8 immune-mediated damage following liver injury, 57 and hepatocellular carcinoma. 9 Alternatively, for peripheral diseases that may benefit from temporary blockade of the TREM2 pathway such as early in respiratory viral infection 35 and certain cancers in which a robust immune response would be beneficial, 38-39 the T3 antagonist NH-3 could be employed. However, during later stages of viral infection when cytokine storm can present, as can occur in COVID-19 critical illness, activation of the TREM2 pathway by sobetirome to drive macrophages to transition to an anti-inflammatory, resolving phenotype would be more appropriate for therapeutic benefit. [58] [59] The CNS-penetrating sobetirome prodrug Sob-AM2 would be the appropriate agent for AD, MS, and other neurodegenerative diseases for which therapeutic benefit would potentially come from TREM2 activation in the CNS while minimizing TREM2 activation and other thyromimetic activity in the periphery. And finally, should there be an application for blocking TREM2 activation in the CNS, the N-methyl amide prodrug of antagonist NH-3 provides enhanced distribution of NH-3 to the CNS while minimizing T3 antagonism in the periphery. 60 In conclusion, we have found that TREM2 is a direct target gene of thyroid hormone, making TREM2 and its signaling pathway in macrophages and microglia subject to regulation by a major endocrine system. To our knowledge ours is the first report of endogenous regulation of TREM2 at the level of gene expression, and it is likely to have important physiological and pathophysiological ramifications for TREM2-mediated innate immunity. This finding also represents a path toward developing small molecule therapeutics that either activate or suppress the TREM2 signaling pathway selectively in the CNS or periphery. The ability to "drug" TREM2 and its pathway with small molecule agents possessing good, drug-like properties would be an important medical advance for the diverse collection of diseases that intersect with TREM2 biology.

Reagents. T3 was purchased and used as received from Sigma-Aldrich. Sobetirome, Sob-AM2, and NH-3 were prepared as described in the literature. 14 Statistical analysis. Statistical significance was determined using 1-way ANOVA with Dunnett's post-test or two-tailed, unpaired Student's t tests between two groups and then plotted together graphically as denoted in each figure legend (P < 0.05). For in vivo experiments, there were no differences in effects between the different vehicles (8 mM NaOH in saline or 50% DMSO in saline), so data from the different vehicles were combined into a single vehicle control group.

Replicates for each experiment were as stated in the specific figure legend and in the corresponding methods. Sample sizes for animal experiments were informed by previous literature accounts or from preliminary data to minimize total animal numbers as appropriate.

Analysis was carried out in GraphPad Prism 8 without further modifications. The ROUT method was used to identify and eliminate outliers. Significance level was set to *P RT-qPCR of mouse RAW264.7 macrophage cells (a) and mouse primary lung macrophages (b-d) stimulated with 10 μg/mL SARS-CoV-2 S1 protein with and without treatment with 10 nM T3 (n = 5-7 as denoted). T3 treatment suppresses pro-inflammatory cytokine expression (Il6 and Il1b, a-c) and upregulates Trem2 expression following inflammatory stimulation with the S1 protein(d). Statistical significance was determined by a 2-tailed, unpaired t test for comparisons between vehicle and group then were plotted together. Asterisks represent significant difference from vehicle unless otherwise noted (*P were quantified. T3 and Sob-AM2 increased TREM2 expression four-fold and three-fold compared to vehicle, respectively. Data represents images from vehicle (n = 18), T3 (n = 12), and Sob-AM2 (n = 12). Two sections were used from each mouse. Significance was determined using one-way ANOVA (P < 0.05). (e) ELISA measurement of TREM2 in spinal cord extracts from the same cohorts of EAE mice (n = 3) used in a-d. (f) Daily EAE clinical disease scores from vehicle (n = 18), T3 (0.4 mg/kg, n = 15), and Sob-AM2 (1 mg/kg, n = 28) treated cohorts. Statistical significance was determined by a two-tailed, unpaired t test comparing vehicle and treatment group per day with each t test performed independently. Asterisks represent significant difference from vehicle unless otherwise noted. (*P 

Physiological and Molecular Basis of Thyroid Hormone Action

Thyroid Hormones as Modulators of Immune Activities at the Cellular Level

The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway

The TREM2-DAP12 signaling pathway in Nasu

The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages

Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy

Structure-Activity Relationships of Central Nervous System Penetration by Fatty Acid Amide Hydrolase (FAAH)-Targeted Thyromimetic Prodrugs

Sobetirome: a case history of bench-to-clinic drug discovery and development

Rational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator Recruitment

Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway

SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro

Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. American journal of respiratory and critical care medicine

TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells

TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer

High TREM2 expression correlates with poor prognosis in gastric cancer

The Emerging Role of Triggering Receptor Expressed on

Myeloid Cells 2 as a Target for Immunomodulation in Ischemic Stroke

TREM2 Variants in Alzheimer's Disease

Variant of TREM2 associated with the risk of Alzheimer's disease

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease

Increased Cerebrospinal Fluid Levels of 3,3′,5′-Triiodothyronine in Patients with Alzheimer's Disease

Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer's disease

Thyroid function and cognitive decline in the MRC Cognitive Function and Ageing Study

Thyroid hormone levels in the prefrontal cortex of post-mortem brains of Alzheimer's disease patients

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease

Associations of thyroid hormone serum levels with in-vivo Alzheimer's disease pathologies

Alzheimer's research & therapy

Prevalence of thyroid dysfunction and its impact on cognition in older mexican adults: (SADEM study)

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation

TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis

Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis

Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models

TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis

Non-parenchymal TREM-2 protects the liver from immunemediated hepatocellular damage

COVID-19: consider cytokine storm syndromes and immunosuppression

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators

Sobetirome prodrug esters with enhanced blood-brain barrier permeability

New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3

Biosynthesis of 3-Iodothyronamine (T1AM) Is Dependent on the Sodium-Iodide Symporter and Thyroperoxidase but Does Not Involve Extrathyroidal Metabolism of T4

A new mathematical model for relative quantification in real-time RT-PCR

Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics

Tollip, an early regulator of the acute inflammatory response in the substantia nigra

Interleukin-10 inhibits interleukin-1β production and inflammasome activation of microglia in epileptic seizures

Isoforskolin downregulates proinflammatory responses induced by Borrelia burgdorferi basic membrane protein A

Cosmosiin Increases ADAM10 Expression via Mechanisms Involving 5'UTR and

Dendritic Cells Expressing Triggering Receptor Expressed on Myeloid Cells-1 Correlate with Plaque Stability in Symptomatic and Asymptomatic Patients with Carotid Stenosis